SM 21

Drug Profile

SM 21

Alternative Names: SM-21

Latest Information Update: 30 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Developer Nonindustrial source; Sumitomo Pharmaceuticals
  • Class Analgesics; Butyrates; Neuroprotectants; Nootropics; Tropanes
  • Mechanism of Action Acetylcholine stimulants; Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Dementia; Pain

Most Recent Events

  • 25 Mar 2004 Discontinued - Preclinical for Pain in Italy (unspecified route)
  • 10 Oct 2003 Discontinued - Preclinical for Dementia in Italy (unspecified route)
  • 29 Jun 2001 No-Development-Reported for Dementia in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top